US and EU industry push for progress with MRA (Mutual Recognition Agreement) implementation
This article was originally published in Clinica
Now that the first phase of the mutual recognition agreement (MRA) between the US and the European Union is on track to begin in the first week of December, regulators must move quickly to develop an action plan that can monitor progress and resolve problematic issues, say representatives from the medical device industry on both sides of the Atlantic.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.